The UK-based Vectura Group plc group has found itself at the center of a power struggle between private equity firm Carlyle and tobacco giant Philip Morris International after both parties raised their prospective bids to take control of the company but did not declare them final, meaning an auction will now decide the victor.
Vectura Heads To Auction As Carlyle And Philip Morris Raise Stakes
Both Parties Submitted Increased Proposals For UK Respiratory Firm
Private equity group Carlyle and tobacco giant Philip Morris International are caught in a tug-of-war for UK-based respiratory specialist Vectura, after submitting revised bids for the company.
More from Deals
More from Business
Gedeon Richter has filed its Mochida-partnered tocilizumab biosimilar rival to RoActemra with the European Medicines Agency. But with several biosimilars already having won approval, the market could be competitive.
• By
Accord received positive opinions for its Prolia and Xgeva biosimilars at the latest meeting of the EMA’s CHMP. Meanwhile, Celltrion picked up a nod for another Stelara biosimilar, while Rechon Life Science withdrew an application for human insulin.
• By
With Celltrion having just received approval for its US Actemra (tocilizumab) biosimilar and having just launched its ustekinumab rival to Stelara – and with the introduction of the Korean developer’s denosumab rivals to Prolia and Xgeva just around the corner – 2025 is set to be a busy year, Celltrion USA chief commercial officer Thomas Nusbickel tells Generics Bulletin.